Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in FGFR-altered recurrent glioblastoma and other CNS tumors
NCT05267106Phase 2Terminated
- Sponsor
- Incyte
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 9
01
Overview
Phase 2, open-label trial of pemigatinib in glioblastoma (GBM), glioma, astrocytic glioma and 2 more (2 cohorts), sponsored by Incyte. Primary endpoint: Objective Response Rate in Participants With Recurrent Glioblastoma Based on Independent Central Review up to 651 days. Started May 2022; status: terminated.
02
Drugs
pemigatinib
03
Conditions
glioblastoma (GBM)gliomaastrocytic gliomaglioneuronal tumorNeuronal and Mixed Neuronal-Glial Tumors
Beyond the preview
Go deeper on NCT05267106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267106.